Galectin Therapeutics (NASDAQ:GALT) with $11 Target Got Coverage By B. Riley FBR On Feb 14, 2019.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Corporate Logo

Big Money Sentiment decreased to 1.29 in 2018 Q3. It has change of 0.21, from 2018Q2’s 1.5. The ratio fall due to Galectin Therapeutics, Inc. positioning: 14 sold and 7 reduced. 12 funds acquired stakes and 15 increased stakes. Investors holded 4.60 million in 2018Q2 but now own 5.15 million shares or 11.86% more.

First Foundation Advsr has invested 0.08% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Millennium Mgmt Ltd holds 0% or 112,399 shs in its capital. Hrt Lc invested in 0.01% or 15,050 shs. Pnc Fin Svcs Group Inc invested in 0% or 47,164 shs. State Street reported 43,378 shs. Deutsche Bankshares Ag owns 2 shs. Natl Bank Of Montreal Can has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Lpl Fin Lc reported 29,793 shs. Next Fincl Group holds 1,000 shs or 0% of its capital. Moreover, Virtu Financial Limited Co has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 17,752 shs. New York-based Benchmark Cap Advsrs has invested 1.01% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Goldman Sachs has 0% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Geode Capital Management Ltd Liability invested 0% of its capital in Galectin Therapeutics, Inc. (NASDAQ:GALT). Blackrock owns 601,657 shs for 0% of their capital. 689,278 were reported by Da Davidson Com.

Galectin Therapeutics, Inc. had 4 selling transactions and 5 insider buys since August 30, 2018. This’s net activity of $419,677. Another trade for 1,000 shs valued at $4,805 was made by LEWIS JOEL on Tuesday, January 29. Another trade for 30,000 shs valued at $150,000 was made by AMELIO GILBERT F on Wednesday, January 30. ELDRED KARY bought 2,000 shs worth $12,200. FREEMAN KEVIN D bought $6,428 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) on Friday, February 8. On Monday, January 28 51,500 shs were bought by Uihlein Richard E, worth $250,559. $116,585 worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) was sold by OMENN GILBERT S.

What Price Target Has B. Riley FBR Given Galectin Therapeutics (NASDAQ:GALT)

upside potential of 138.61 % on Galectin Therapeutics (NASDAQ:GALT) would suggest $11 PT given by Equity analysts at B. Riley FBR. Also on 13 February coverage began by broker on the $207.11 million market cap company.

GALT reached $4.61 during the last trading session after $0.15 change.Galectin Therapeutics, Inc. has 366,649 shares volume, 53.55% up from normal. GALT is uptrending and has moved 150.25% since February 14, 2018. The stock outperformed the S&P500 by 150.25%.

Galectin Therapeutics, Inc. (NASDAQ:GALT)’s earnings release is expected by WallStreet on April, 4, as reported by RTT. EPS of $-0.08 is 14.29 % down from 2018’s $-0.07 EPS. Wall Street now forecasts 14.29 % negative EPS growth despite Galectin Therapeutics, Inc. previous quarter’s EPS of $-0.07.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer.The firm is valued at $207.11 million. The company's lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.Currently it has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

For more Galectin Therapeutics, Inc. (NASDAQ:GALT) news published recently go to: Nasdaq.com, Nasdaq.com, Zacks.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Conatus (CNAT) Completes Enrollment in Phase II NASH Study – Nasdaq” published on February 13, 2019, “Is Galectin Therapeutics (GALT) Stock Outpacing Its Medical Peers This Year? – Nasdaq” on January 30, 2019, “Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock? – Zacks.com” with a publish date: January 04, 2019, “Mid-Afternoon Market Update: Precipio Surges Following Strong Preliminary Q1 Results; aTyr Pharma Shares Slide – Nasdaq” and the last “Key events next week – healthcare – Seeking Alpha” with publication date: November 05, 2018.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.